A citation-based method for searching scientific literature

Mark D Stewart, Diana Merino Vega, Rebecca C Arend, Jonathan F Baden, Olena Barbash, Nike Beaubier, Grace Collins, Tim French, Negar Ghahramani, Patsy Hinson, Petar Jelinic, Matthew J Marton, Kimberly McGregor, Jerod Parsons, Lakshman Ramamurthy, Mark Sausen, Ethan S Sokol, Albrecht Stenzinger, Hillary Stires, Kirsten M Timms, Diana Turco, Iris Wang, J Andrew Williams, Elaine Wong-Ho, Jeff Allen. Oncologist 2022
Times Cited: 3







List of co-cited articles
4 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.
Debyani Chakravarty, Amber Johnson, Jeffrey Sklar, Neal I Lindeman, Kathleen Moore, Shridar Ganesan, Christine M Lovly, Jane Perlmutter, Stacy W Gray, Jimmy Hwang,[...]. J Clin Oncol 2022
4
66

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Mark Robson, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Susan M Domchek, Norikazu Masuda, Suzette Delaloge, Wei Li, Nadine Tung, Anne Armstrong,[...]. N Engl J Med 2017
66

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
Jennifer K Litton, Hope S Rugo, Johannes Ettl, Sara A Hurvitz, Anthony Gonçalves, Kyung-Hun Lee, Louis Fehrenbacher, Rinat Yerushalmi, Lida A Mina, Miguel Martin,[...]. N Engl J Med 2018
825
66

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
Maha Hussain, Joaquin Mateo, Karim Fizazi, Fred Saad, Neal Shore, Shahneen Sandhu, Kim N Chi, Oliver Sartor, Neeraj Agarwal, David Olmos,[...]. N Engl J Med 2020
193
66

Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer.
W D Foulkes, N Wong, J S Brunet, L R Bégin, J C Zhang, J J Martinez, F Rozen, P N Tonin, S A Narod, S E Karp,[...]. Clin Cancer Res 1997
96
33

BRCA2 acts as a RAD51 loader to facilitate telomere replication and capping.
Sophie Badie, Jose M Escandell, Peter Bouwman, Ana Rita Carlos, Maria Thanasoula, Maria M Gallardo, Anitha Suram, Isabel Jaco, Javier Benitez, Utz Herbig,[...]. Nat Struct Mol Biol 2010
122
33

Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study.
Pamela J Goodwin, Kelly-Anne Phillips, Dee W West, Marguerite Ennis, John L Hopper, Esther M John, Frances P O'Malley, Roger L Milne, Irene L Andrulis, Michael L Friedlander,[...]. J Clin Oncol 2012
100
33

Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy.
Nicola J Curtin, Yvette Drew, Sweta Sharma-Saha. Nat Rev Clin Oncol 2019
13
33

Survival and recurrence after breast cancer in BRCA1/2 mutation carriers.
Mahmoud El-Tamer, Donna Russo, Andrea Troxel, Lourdes P Bernardino, Robert Mazziotta, Alison Estabrook, Beth-Ann Ditkoff, Freya Schnabel, Mahesh Mansukhani. Ann Surg Oncol 2004
44
33

Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
S Loibl, K E Weber, K M Timms, E P Elkin, E Hahnen, P A Fasching, B Lederer, C Denkert, A Schneeweiss, S Braun,[...]. Ann Oncol 2018
122
33

TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial).
Nadine Tung, Banu Arun, Michele R Hacker, Erin Hofstatter, Deborah L Toppmeyer, Steven J Isakoff, Virginia Borges, Robert D Legare, Claudine Isaacs, Antonio C Wolff,[...]. J Clin Oncol 2020
52
33

Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study).
Naohiro Okano, Chigusa Morizane, Shogo Nomura, Hideaki Takahashi, Hidetaka Tsumura, Hironaga Satake, Nobumasa Mizuno, Kunihiro Tsuji, Kazuhiko Shioji, Akinori Asagi,[...]. Int J Clin Oncol 2020
5
33

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
Andrew N J Tutt, Judy E Garber, Bella Kaufman, Giuseppe Viale, Debora Fumagalli, Priya Rastogi, Richard D Gelber, Evandro de Azambuja, Anitra Fielding, Judith Balmaña,[...]. N Engl J Med 2021
202
33

Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.
Joyce O'Shaughnessy, Lee Schwartzberg, Michael A Danso, Kathy D Miller, Hope S Rugo, Marcus Neubauer, Nicholas Robert, Beth Hellerstedt, Mansoor Saleh, Paul Richards,[...]. J Clin Oncol 2014
185
33

Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors.
Wenchao Ji, Xiang Weng, Danhua Xu, Shufan Cai, Honggang Lou, Ling Ding. Biochem Biophys Res Commun 2020
9
33

Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas.
Marthe M de Jonge, Aurélie Auguste, Lise M van Wijk, Philip C Schouten, Matty Meijers, Natalja T Ter Haar, Vincent T H B M Smit, Remi A Nout, Mark A Glaire, David N Church,[...]. Clin Cancer Res 2019
69
33

Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Véronique Diéras, Hyo S Han, Bella Kaufman, Hans Wildiers, Michael Friedlander, Jean-Pierre Ayoub, Shannon L Puhalla, Igor Bondarenko, Mario Campone, Erik H Jakobsen,[...]. Lancet Oncol 2020
95
33

BRCA Genes: The Role in Genome Stability, Cancer Stemness and Therapy Resistance.
Ielizaveta Gorodetska, Iryna Kozeretska, Anna Dubrovska. J Cancer 2019
72
33

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Sibylle Loibl, Joyce O'Shaughnessy, Michael Untch, William M Sikov, Hope S Rugo, Mark D McKee, Jens Huober, Mehra Golshan, Gunter von Minckwitz, David Maag,[...]. Lancet Oncol 2018
328
33

Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer.
Jeffrey A How, Amir A Jazaeri, Bryan Fellman, Molly S Daniels, Suzanna Penn, Cara Solimeno, Ying Yuan, Kathleen Schmeler, Jerry S Lanchbury, Kirsten Timms,[...]. Cancers (Basel) 2021
10
33

Homologous recombination in DNA repair and DNA damage tolerance.
Xuan Li, Wolf-Dietrich Heyer. Cell Res 2008
524
33

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration.
Wassim Abida, Akash Patnaik, David Campbell, Jeremy Shapiro, Alan H Bryce, Ray McDermott, Brieuc Sautois, Nicholas J Vogelzang, Richard M Bambury, Eric Voog,[...]. J Clin Oncol 2020
200
33

Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma.
David Fogelman, Elizabeth A Sugar, George Oliver, Neeraj Shah, Alison Klein, Christine Alewine, Huamin Wang, Milind Javle, Rachna Shroff, Robert A Wolff,[...]. Cancer Chemother Pharmacol 2015
43
33

Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms.
Maeve A Lowery, Winston Wong, Emmet J Jordan, Jonathan W Lee, Yelena Kemel, Joseph Vijai, Diana Mandelker, Ahmet Zehir, Marinela Capanu, Erin Salo-Mullen,[...]. J Natl Cancer Inst 2018
110
33

Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations.
Jose Mauricio Mota, Ethan Barnett, Jones T Nauseef, Bastien Nguyen, Konrad H Stopsack, Andreas Wibmer, Jessica R Flynn, Glenn Heller, Daniel C Danila, Dana Rathkopf,[...]. JCO Precis Oncol 2020
48
33

Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.
Junko Murai, Shar-Yin N Huang, Amèlie Renaud, Yiping Zhang, Jiuping Ji, Shunichi Takeda, Joel Morris, Beverly Teicher, James H Doroshow, Yves Pommier. Mol Cancer Ther 2014
433
33

Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer.
Tamara L Lotan, Harsimar B Kaur, Daniela C Salles, Sanjana Murali, Edward M Schaeffer, Jerry S Lanchbury, William B Isaacs, Robert Brown, Andrea L Richardson, Olivier Cussenot,[...]. Mod Pathol 2021
21
33

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
Melinda L Telli, Kirsten M Timms, Julia Reid, Bryan Hennessy, Gordon B Mills, Kristin C Jensen, Zoltan Szallasi, William T Barry, Eric P Winer, Nadine M Tung,[...]. Clin Cancer Res 2016
444
33

Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.
Eric Hahnen, Bianca Lederer, Jan Hauke, Sibylle Loibl, Sandra Kröber, Andreas Schneeweiss, Carsten Denkert, Peter A Fasching, Jens U Blohmer, Christian Jackisch,[...]. JAMA Oncol 2017
196
33

Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival.
Asima Mukhopadhyay, Elizabeth R Plummer, Ahmed Elattar, San Soohoo, Bisha Uzir, Jennifer E Quinn, W Glenn McCluggage, Perry Maxwell, Harriet Aneke, Nicola J Curtin,[...]. Cancer Res 2012
77
33

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
Mansoor R Mirza, Bradley J Monk, Jørn Herrstedt, Amit M Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A Ledermann, Domenica Lorusso, Ignace Vergote,[...]. N Engl J Med 2016
33

Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity.
Ethan S Sokol, Dean Pavlick, Hossein Khiabanian, Garrett M Frampton, Jeffrey S Ross, Jeffrey P Gregg, Primo N Lara, Steffi Oesterreich, Neeraj Agarwal, Andrea Necchi,[...]. JCO Precis Oncol 2020
52
33

Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
Johann S de Bono, Niven Mehra, Giorgio V Scagliotti, Elena Castro, Tanya Dorff, Adam Stirling, Arnulf Stenzl, Mark T Fleming, Celestia S Higano, Fred Saad,[...]. Lancet Oncol 2021
36
33

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.
Panagiotis A Konstantinopoulos, Raphael Ceccaldi, Geoffrey I Shapiro, Alan D D'Andrea. Cancer Discov 2015
422
33

Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience.
Banu Arun, Soley Bayraktar, Diane D Liu, Angelica M Gutierrez Barrera, Deann Atchley, Lajos Pusztai, Jennifer Keating Litton, Vicente Valero, Funda Meric-Bernstam, Gabriel N Hortobagyi,[...]. J Clin Oncol 2011
114
33

Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.
Max M Wattenberg, Daniella Asch, Shun Yu, Peter J O'Dwyer, Susan M Domchek, Katherine L Nathanson, Mark A Rosen, Gregory L Beatty, Evan S Siegelman, Kim A Reiss. Br J Cancer 2020
76
33

Retrospective Survival Analysis of Patients With Advanced Pancreatic Ductal Adenocarcinoma and Germline BRCA or PALB2 Mutations.
Kim A Reiss, Shun Yu, Renae Judy, Heather Symecko, Katherine L Nathanson, Susan M Domchek. JCO Precis Oncol 2018
9
33

Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program.
Michael J Pishvaian, Edik M Blais, Jonathan R Brody, Lola Rahib, Emily Lyons, Patricia De Arbeloa, Andrew Hendifar, Sameh Mikhail, Vincent Chung, Davendra P S Sohal,[...]. JCO Precis Oncol 2019
10
33

FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer.
Shaily Arora, Sanjeeve Balasubramaniam, Hui Zhang, Tara Berman, Preeti Narayan, Daniel Suzman, Erik Bloomquist, Shenghui Tang, Yutao Gong, Rajeshwari Sridhara,[...]. Oncologist 2021
34
33

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S Sonke,[...]. N Engl J Med 2018
33

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Joaquin Mateo, Suzanne Carreira, Shahneen Sandhu, Susana Miranda, Helen Mossop, Raquel Perez-Lopez, Daniel Nava Rodrigues, Dan Robinson, Aurelius Omlin, Nina Tunariu,[...]. N Engl J Med 2015
33

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
Robert L Coleman, Gini F Fleming, Mark F Brady, Elizabeth M Swisher, Karina D Steffensen, Michael Friedlander, Aikou Okamoto, Kathleen N Moore, Noa Efrat Ben-Baruch, Theresa L Werner,[...]. N Engl J Med 2019
360
33

Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.
F Mosele, J Remon, J Mateo, C B Westphalen, F Barlesi, M P Lolkema, N Normanno, A Scarpa, M Robson, F Meric-Bernstam,[...]. Ann Oncol 2020
238
33


Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents.
Nicolai J Birkbak, Zhigang C Wang, Ji-Young Kim, Aron C Eklund, Qiyuan Li, Ruiyang Tian, Christian Bowman-Colin, Yang Li, April Greene-Colozzi, J Dirk Iglehart,[...]. Cancer Discov 2012
296
33

Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status.
Pal Moller, D Gareth Evans, Marta M Reis, Helen Gregory, Elaine Anderson, Lovise Maehle, Fiona Lalloo, Anthony Howell, Jaran Apold, Neal Clark,[...]. Int J Cancer 2007
69
33

Efficacy of platinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: comparative analysis of published clinical studies.
Ilya Pokataev, Mikhail Fedyanin, Elizaveta Polyanskaya, Anna Popova, Julia Agafonova, Sophia Menshikova, Alexey Tryakin, Alexey Rumyantsev, Sergei Tjulandin. ESMO Open 2020
15
33

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Hannah Farmer, Nuala McCabe, Christopher J Lord, Andrew N J Tutt, Damian A Johnson, Tobias B Richardson, Manuela Santarosa, Krystyna J Dillon, Ian Hickson, Charlotte Knights,[...]. Nature 2005
33

Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations.
S Bayraktar, A M Gutierrez-Barrera, H Lin, N Elsayegh, T Tasbas, J K Litton, N K Ibrahim, P K Morrow, M Green, V Valero,[...]. Clin Exp Metastasis 2013
24
33

Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer.
Talia Golan, Alex Barenboim, Guy Lahat, Ido Nachmany, Yacov Goykhman, Einat Shacham-Shmueli, Naama Halpern, Eli Brazowski, Ravit Geva, Ido Wolf,[...]. Ann Surg Oncol 2020
32
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.